# Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2

> **NCT02719756** · PHASE4 · UNKNOWN · sponsor: **Research Clinical Centre of the Russian Railways, JSC** · enrollment: 100 (estimated)

## Conditions studied

- Diabetes Mellitus
- Hypoglycemic Episodes

## Interventions

- **DRUG:** Metformin
- **DRUG:** Dapagliflozin
- **DRUG:** Metformin up-titration

## Key facts

- **NCT ID:** NCT02719756
- **Lead sponsor:** Research Clinical Centre of the Russian Railways, JSC
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-04
- **Primary completion:** 2016-10
- **Final completion:** 2016-12
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2016-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02719756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02719756, "Effect of SGLT-2 Inhibitor Dapagliflozin on Glycemic Variability in Patients With Diabetes Mellitus Type 2". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02719756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*